Topic:

Analytical Testing

Latest Headlines

Latest Headlines

Charles River amps up its biologics testing

Charles River Laboratories is kicking off an all-encompassing service that will allow its biotech and pharma clients to hand over their quality-control testing for biologics en masse, a method the preclinical CRO says can save time and money.

Theorem teams with Charles River on preclinical work

Theorem Clinical Research has struck a deal with Charles River Laboratories, adding the early-phase-focused CRO's capabilities to its drug development platform.

After Warnex buy, Biotrial jumps into bioanalytics

Now that it has paid about $6.1 million for Warnex's bioanalytics business, France's Biotrial Research is launching an offering all its own.

Solvias buys quality control business

Swiss CRO Solvias has bought Confarma, a French quality control consultancy.

Recipharm bets on analytical development with expansion

Swedish CDMO Recipharm is banking on a growing demand for analytical drug development services, planning to reconstruct its Solna, Sweden, facility to house its data-based offerings.

Charles River pays $27M for majority of Chinese company

Charles River Laboratories has inked a $27 million deal for 75% of Chinese research model design company Vital River.

Small CROs band together to better compete

Six small CROs are pooling their resources and joining together, looking to capitalize on what they see as a hole in the market for contract research.

Covance taps big data outfit for diabetes R&D

Covance is joining forces with GNS Healthcare to use the company's big data know-how to create models for drug-development success.

CoreRx triples capacity with Florida plant

CoreRx has moved into its new 35,000-square-foot facility in Clearwater, FL, and the new lab will more than triple the CRO's daily capactiy, the company said.

Quintiles survey shows U.S. and U.K. payers want to improve R&D with increased involvement

Based on the findings published in Quintiles' annual "New Health Report," payers want to get the ball rolling sooner to get drugs approved faster.